Hong Shi
Research Subjects
Hong Shi has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Ashleigh Hahn
GSK, Collegeville, Pennsylvania
95 shared publications - Axel Hoos
Scorpion Therapeutics, Boston, Massachusetts
95 shared publications - Catherine Ellis
GSK, Collegeville, USA
95 shared publications - Christina Blackwell
GSK, Collegeville, Pennsylvania
95 shared publications - Christopher B. Hopson
GSK, Collegeville, Pennsylvania
95 shared publications - Daniel Olive
Team Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, CNRS UMR 7258, Aix-Marseille University UM105 and Paoli-Calmettes Institute, Marseille, France
95 shared publications
Latest Publications
- Open Access
- 16 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Movie 1 Legend from Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade
Expression dynamics and cellular localization of ICOS.
- 16 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Movie 1 Legend from Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade
Expression dynamics and cellular localization of ICOS.
- Open Access
- 16 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade
Gene expression in human T-cell
- 16 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade
Gene expression in human T-cell
- Open Access
- 16 August 2023
- Published by American Association for Cancer Research (AACR)
FIGURE 5 from Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade
Clinical patient case studies of feladilimab monotherapy and in combination with pembrolizumab. A, Clinical history and treatment details for a patient with melanoma who received feladilimab monotherapy and a patient with oropharyngeal squamous cell carcinoma who received feladilimab in combination with pembrolizumab. Tumor sample immunohistochemistry and expression of markers for TIL activation, cytotoxic function and proliferation for the monotherapy case study (B) and the combination therapy case study (C). See Supplementary Fig. S11B for CT imaging of tumor lesions for the patient with oropharyngeal squamous cell carcinoma. CPS, combined positive score; CT, computed tomography; HLA-DR, human leukocyte antigen-DR; HPV, human papillomavirus; PD-L1, programmed death ligand-1; TIL, tumor-infiltrating lymphocyte.
- 16 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 5 from Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade
Clinical patient case studies of feladilimab monotherapy and in combination with pembrolizumab. A, Clinical history and treatment details for a patient with melanoma who received feladilimab monotherapy and a patient with oropharyngeal squamous cell carcinoma who received feladilimab in combination with pembrolizumab. Tumor sample immunohistochemistry and expression of markers for TIL activation, cytotoxic function and proliferation for the monotherapy case study (B) and the combination therapy case study (C). See Supplementary Fig. S11B for CT imaging of tumor lesions for the patient with oropharyngeal squamous cell carcinoma. CPS, combined positive score; CT, computed tomography; HLA-DR, human leukocyte antigen-DR; HPV, human papillomavirus; PD-L1, programmed death ligand-1; TIL, tumor-infiltrating lymphocyte.
- Open Access
- 16 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade
Example TIL marker expression phenotypes from clinical patient case studies of feladilimab monotherapy and in combination with pembrolizumab.
- 16 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade
Example TIL marker expression phenotypes from clinical patient case studies of feladilimab monotherapy and in combination with pembrolizumab.
- Open Access
- 16 August 2023
- Published by American Association for Cancer Research (AACR)
FIGURE 3 from Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade
ICOS agonist mAbs demonstrate single-agent antitumor activity. A–C, EMT6 (subcutaneous) tumor-bearing BALB/c mice were administered intraperitoneally biweekly with anti-mouse ICOS mAb [7E.17G9 (mIgG1)] or isotype control (mIgG1) for a total of six doses and evaluated for tumor growth (A), survival (B), and pharmacodynamic changes (C) within tumors. Each line in A represents an individual mouse (n = 10/group). Number of tumor-free mice at study termination are indicated within each subpanel. B, Kaplan–Meier plot illustrating OS in A. C, Percentage of tumor-infiltrating CD8+ T cells, Treg cells, and associated CD8:Treg cell ratio 48 hours after the third dose of anti-ICOS mAb (10 μg, ∼study day 7) assessed using flow cytometry (nonspecific binding was blocked with human or mouse Fc block). Each symbol represents an individual mouse. D–F, A549 (subcutaneous) tumor-bearing NSG mice were administered intraperitoneally biweekly with feladilimab or isotype control for a total of six doses. D, A549 tumor growth kinetics for controls (PBS or isotype) and feladilimab-treated groups (0.04 mg/kg, black; 0.4 mg/kg, red). Percentage of tumor-infiltrating ICOS+ CD8+ T cells (E; assessed using flow cytometry with nonspecific binding blocked using human or mouse Fc block) and associated CD8:Treg cell ratio (F) 48 hours after the fourth dose of feladilimab (∼study day 21). Data in C, D, E, and F represent the mean ± s.e.m. Significance was determined by unpaired Student t test. See Supplementary Fig. S1 for flow cytometry gating strategy for C, E, and F. CD8/Treg ratios were calculated on the basis of percent (%) positive CD8s (of live CD45+) and FoxP3/CD25+ Treg cells (of live CD45+ CD4+ cells). ICOS, inducible T-cell costimulator; i.p., intraperitoneal injection; mAb, monoclonal antibody; OS, overall survival; s.e.m., standard error of the mean.
- 16 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 3 from Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade
ICOS agonist mAbs demonstrate single-agent antitumor activity. A–C, EMT6 (subcutaneous) tumor-bearing BALB/c mice were administered intraperitoneally biweekly with anti-mouse ICOS mAb [7E.17G9 (mIgG1)] or isotype control (mIgG1) for a total of six doses and evaluated for tumor growth (A), survival (B), and pharmacodynamic changes (C) within tumors. Each line in A represents an individual mouse (n = 10/group). Number of tumor-free mice at study termination are indicated within each subpanel. B, Kaplan–Meier plot illustrating OS in A. C, Percentage of tumor-infiltrating CD8+ T cells, Treg cells, and associated CD8:Treg cell ratio 48 hours after the third dose of anti-ICOS mAb (10 μg, ∼study day 7) assessed using flow cytometry (nonspecific binding was blocked with human or mouse Fc block). Each symbol represents an individual mouse. D–F, A549 (subcutaneous) tumor-bearing NSG mice were administered intraperitoneally biweekly with feladilimab or isotype control for a total of six doses. D, A549 tumor growth kinetics for controls (PBS or isotype) and feladilimab-treated groups (0.04 mg/kg, black; 0.4 mg/kg, red). Percentage of tumor-infiltrating ICOS+ CD8+ T cells (E; assessed using flow cytometry with nonspecific binding blocked using human or mouse Fc block) and associated CD8:Treg cell ratio (F) 48 hours after the fourth dose of feladilimab (∼study day 21). Data in C, D, E, and F represent the mean ± s.e.m. Significance was determined by unpaired Student t test. See Supplementary Fig. S1 for flow cytometry gating strategy for C, E, and F. CD8/Treg ratios were calculated on the basis of percent (%) positive CD8s (of live CD45+) and FoxP3/CD25+ Treg cells (of live CD45+ CD4+ cells). ICOS, inducible T-cell costimulator; i.p., intraperitoneal injection; mAb, monoclonal antibody; OS, overall survival; s.e.m., standard error of the mean.
- Open Access
- 16 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade
Flow cytometry gating strategy for ICOS on individual T cell populations.
- 16 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade
Flow cytometry gating strategy for ICOS on individual T cell populations.
- Open Access
- 16 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 10 from Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade
Rationale for combination of feladilimab with anti–PD-1 blockade.
- 16 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 10 from Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade
Rationale for combination of feladilimab with anti–PD-1 blockade.